Vertice Pharma announced the launch of Thyquidity™ (levothyroxine sodium) oral solution.

Thyquidity is indicated for the treatment of hypothyroidism – as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. 1 Liter Glass Bottle With Lid

Thyquidity Oral Solution Now Available for Hypothyroidism - MPR

It is also approved for pituitary thyrotropin suppression as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.

The product is supplied in 100mL amber glass bottles containing 100mcg of levothyroxine sodium per 5mL. Thyquidity should be administered directly to the mouth using a calibrated oral syringe.

Latest News Your top articles for Friday

Haymarket Medical Network Top Picks

Continuing Medical Education (CME/CE) Courses

Please login or register first to view this content.

Thyquidity Oral Solution Now Available for Hypothyroidism - MPR

1000ml Glass Bottle For Olive Oil Copyright © 2023 Haymarket Media, Inc. All Rights Reserved. This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms & Conditions.